PPARγ agonists delay age-associated metabolic disease and extend longevity

Area of Science:

• Gerontology and Molecular Medicine
• Pharmacology and Therapeutics

Background:

• Cellular senescence, tissue damage, and organ dysfunction contribute to aging and associated disorders.
• Anti-inflammatory and insulin-sensitizing compounds may delay aging and prevent age-related diseases, enhancing healthspan and lifespan.

Purpose of the Study:

• To investigate the effects of Peroxisome proliferator-activated receptor gamma (PPARγ) agonists on aging and longevity.
• To evaluate the potential of PPARγ agonists in preventing age-related decline and extending lifespan.

Main Methods:

• Long-term administration of low-dose rosiglitazone (Rosi), a PPARγ ligand, to middle-aged mice (14 months old).
• Molecular and physiological assessments of glucose metabolism, mitochondrial function, inflammation, tissue atrophy, cognitive function, and mood-related behaviors.
• Retrospective analysis of pioglitazone (Pio) effects on mortality in patients compared to glimepiride.

Main Results:

• Rosiglitazone treatment improved glucose metabolism and mitochondrial functionality in mice.
• Observed reductions in inflammation and tissue atrophy, alongside improvements in cognitive function and mood.
• Rosiglitazone treatment initiated in middle age extended mouse lifespan without adverse cardiac or skeletal effects.
• Pioglitazone use was associated with decreased mortality in human patients compared to glimepiride.

Conclusions:

• PPARγ agonists demonstrate potential for promoting healthy aging and extending lifespan.
• These findings suggest that PPARγ agonists could be therapeutic agents for age-related disorders and longevity.
• Further research into PPARγ agonists may pave the way for interventions to enhance human healthspan.